H.C. Wainwright Thinks HTG Molecular Diagnostics’ Stock is Going to Recover
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on HTG Molecular Diagnostics (HTGM) today and set a price target of $1.00. The company’s shares closed last Tuesday at $0.32, close to its 52-week low of $0.27.
According to TipRanks.com, Chen is a 5-star analyst with an average return of 40.8% and a 35.7% success rate. Chen covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, EyePoint Pharmaceuticals, and Aerpio Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for HTG Molecular Diagnostics with a $1.28 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $0.94 and a one-year low of $0.27. Currently, HTG Molecular Diagnostics has an average volume of 2.81M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. Its customers include biopharmaceutical companies, academic research centers, and molecular testing laboratories. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ.
Read More on HTGM: